Tous Actualités
Suivre
Abonner Isotechnika Inc.

Isotechnika Inc.

Isotechnika Inc. receives No Objection Letter from Health Canada for Phase III Psoriasis Trial

Edmonton, Alberta (ots/PRNewswire)

Isotechnika Inc. announced
today that the Company received a No  Objection Letter from Health
Canada for the commencement of a Phase III  trial for its lead
immunosuppressive drug candidate, ISA247.
The trial will be performed over a twenty-four week period at
thirty-  three centers across Canada involving a total of 400
subjects with severe  psoriasis. It will be conducted as a
randomized, double-blind study with  100 subjects receiving the high
dose (0.4 mg/kg twice daily), 100 subjects  receiving the anticipated
therapeutic dose (0.3 mg/kg twice daily),  100 subjects receiving the
low dose (0.2 mg/kg twice daily) and 100  subjects receiving placebo.
In an effort to maximize the benefit to those  enrolled in the study
who may receive placebo for the first 12 week period  they will be
administered a dose of 0.3 mg/kg twice daily commencing the  13th
week of the study. All doses of drug will be administered as soft
gelatine capsules administered orally.
Successful completion of the trial will be determined by the
proportion  of subjects who achieve a 75% reduction in the psoriasis
area and severity  index (PASI). Secondary endpoints of the trial
include maintenance of  stable kidney function and assessment of
quality of life. Blood specimens  will also be collected periodically
to gather additional pharmacokinetic  and pharmacodynamic (PK/PD)
data.
"Moving ISA247 into Phase III has been the Company's primary focus
over  the last year," stated Dr. Randall Yatscoff, Isotechnika's
President and &  COO. "Receipt of the No Objection Letter allows us
to meet the drug  development timelines set for ISA247 and establish
Isotechnika as a Phase  III company. Manufacturing of the drug supply
was completed in an efficient  and cost-effective manner."
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in  medicinal chemistry and immunology, the Company is
focused on the discovery  and development of novel immunosuppressive
therapeutics that are safer than  currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug  candidates for use in
the prevention of organ rejection in transplantation  and in the
treatment of autoimmune diseases. Isotechnika looks to become  the
leader in development of immunosuppressant therapies.
Isotechnika's lead drug, ISA247, presently referred to as
trans-ISA247,  is an immunosuppressant that has successfully
completed a Phase II trial  for psoriasis and Phase IIa trial for
kidney transplantation. Isotechnika  recently expanded its product
pipeline by developing two additional novel  immunosuppressive
compounds, TAFA93 and TKB662. TAFA93 is a novel small  molecule mTOR
inhibitor, a class of drugs currently used in the prevention  of
organ rejection in transplantation and as a coated stent therapy in
the  treatment of coronary artery disease. Pre-clinical studies of
TKB662 have  demonstrated inhibition of T cell and B cell activation
and proliferation  through multiple mechanisms of action including
the inhibition of  lymphocyte phosphorylation activity. As both
TAFA93 and TKB662 have  distinct mechanisms of action from
calcineurin inhibitors such as ISA247  they have the potential to be
administered as complementary therapies in  both prevention of organ
rejection and treatment of autoimmune diseases.
In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(TM) and Diatest(TM)
breath  kits. The Helikit(TM), a (13)C breath test is used for the
detection of  H.pylori, a bacterium that infects a large portion of
the population. The  Helikit(TM) is currently sold internationally.
The Diatest(TM), a (13)C  glucose breath test is used for the
detection of insulin resistance. The  Company expects to commence the
necessary clinical trials in 2005 involving the Diatest(TM) to obtain
regulatory approval in the United States.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found  at www.isotechnika.com.
Forward-Looking Statements
This press release may contain forward-looking statements.
Forward-  looking statements, including the Company's belief as to
the potential of  its products, the Company's expectations regarding
the issuance of  additional patents and the Company's ability to
protect its intellectual  property, involve known and unknown risks
and uncertainties, which could  cause the Company's actual results to
differ materially from those in the  forward- looking statements.
Such risks and uncertainties include, among  others, the availability
of funds and resources to pursue research and  development projects,
the ability to economically manufacture its products,  the potential
of its products, the success and timely completion of  clinical
studies and trials, the Company's ability to successfully
commercialize its products, the ability of the Company to defend its
patents from infringement by third parties, and the risk that the
Company's  patents may be subsequently shown to be invalid or
infringe the patents of  others. Investors should consult the
Company's quarterly and annual filings  with the Canadian commissions
for additional information on risks and  uncertainties relating to
the forward- looking statements. Investors are  cautioned against
placing undue reliance on forward-looking statements.

Contact:

For further information: Dr. Randall Yatscoff, President & COO,
Isotechnika Inc., Phone: +1(780)-487-1600 Ext.246, Fax:
+1-(780)-484-4105, Email: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Manager, Corporate Communications, Isotechnika
Inc., Phone: +1(780)-487-1600 Ext. 243, Fax: +1-(780)-484-4105,
E-mail:sgillis-paulgaard@isotechnika.com

Plus de actualités: Isotechnika Inc.
Plus de actualités: Isotechnika Inc.
  • 03.11.2004 – 14:05

    Isotechnika Inc. Achieves all Endpoints in Multiple Ascending Dose Study for ISA247

    Edmonton, Canada, November 3 (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has successfully completed the multiple ascending dose study for its lead immunosuppressive drug, ISA247. The multiple ascending dose (MAD) study for ISA247 that commenced on June 3, 2004 involved a total of 43 subjects. The study, conducted by SFBC Anapharm in ...

  • 09.09.2004 – 14:06

    Isotechnika Inc. Reports Interim Results of QTc Trial

    Edmonton, Alberta, Canada (ots/PRNewswire) - Isotechnika Inc. announced today they have received the interim results of the QTc trial for its lead immunosuppressive drug, ISA247 from eResearch Technology Inc. The study, conducted by Pracs in Fargo, North Dakota was designed as a double blind, parallel group, placebo and moxifloxacin controlled, randomized, single dose QTc study of trans-ISA247 in healthy volunteers. In ...